FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 341:1632 November 18, 1999 Number 21 Next

	Since this article has no abstract, we have provided an extract of the first 100% of the full text and any section headings.

	Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Drazen, J. M.

Treatment of Asthma with Drugs Modifying the Leukotriene Pathway . On page 201, in Table 2, the oral dose of zafirlukast should have been "20 mg twice daily," not "40 mg twice daily," as printed.

This article has been cited by other articles:

• Lambiase, A., Bonini, S., Rasi, G., Coassin, M., Bruscolini, A., Bonini, S. (2003). Montelukast, a Leukotriene Receptor Antagonist, in Vernal Keratoconjunctivitis Associated With Asthma. Arch Ophthalmol 121: 615-620 [Abstract] [Full Text]